Stock Analysis

CK Life Sciences Int'l. (Holdings) Full Year 2022 Earnings: EPS: HK$0.014 (vs HK$0.017 in FY 2021)

Source: Shutterstock

CK Life Sciences Int'l. (Holdings) (HKG:775) Full Year 2022 Results

Key Financial Results

  • Revenue: HK$5.28b (down 2.3% from FY 2021).
  • Net income: HK$132.0m (down 19% from FY 2021).
  • Profit margin: 2.5% (down from 3.0% in FY 2021). The decrease in margin was driven by lower revenue.
  • EPS: HK$0.014 (down from HK$0.017 in FY 2021).
SEHK:775 Earnings and Revenue History March 15th 2023

All figures shown in the chart above are for the trailing 12 month (TTM) period

CK Life Sciences Int'l. (Holdings) shares are down 4.9% from a week ago.

Risk Analysis

It's still necessary to consider the ever-present spectre of investment risk. We've identified 2 warning signs with CK Life Sciences Int'l. (Holdings), and understanding them should be part of your investment process.

Valuation is complex, but we're helping make it simple.

Find out whether CK Life Sciences Int'l. (Holdings) is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis